The PRE-NUTRITIVE Study
Research type
Research Study
Full title
Predicting REsponses to chemotherapy from NUTRition In Triple NegatIVE Breast Cancer: The PRE-NUTRITIVE Study.
IRAS ID
311845
Contact name
James Thorne
Contact email
Sponsor organisation
University of Leeds
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
Survival of breast cancer patients has improved a lot in the last few decades, but this is not the case for all ‘subtypes’ of breast cancer. Survival is lower if a patient’s tumour is able to ‘resist’ the chemotherapy drugs that are being used to treat the cancer. This is called chemoresistance. When drugs stop working patients need to have their treatment changed. This means that they lose valuable time in the fight against the cancer. The patient may also suffer from unnecessary side-effects. It is unclear why a particular chemotherapy drug works better for one patient but not for other patients. Our previous research suggests that chemical changes to nutrients, known as metabolism, can make the tumour more resistant to drugs. Even before treatment begins cholesterol and other nutrients cause changes in the tumour.The tumour can become chemoresistant because of this and continue to grow even when the patient is receiving treatment.
We want to identify chemotherapy pathways altered by nutrients in breast cancer, and if patients’ nutritional behaviour and life style are in line and demonstrate adherence to the World Cancer Prevention Fund cancer prevention recommendations or not. We will recruit new breast cancer patients and try to predict how their tumours will respond to chemotherapy using this nutrition information. To make these predictions we will use data collected from measuring the activity of the nutrient and chemotherapy genes inside their tumours. We will also collect information about how close their diet is the World Cancer Prevention Fund cancer prevention guidelines.REC name
West Midlands - Solihull Research Ethics Committee
REC reference
22/WM/0087
Date of REC Opinion
11 May 2022
REC opinion
Further Information Favourable Opinion